A monumental achievement for ImmunityBio, Inc. occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. On Mon
A monumental achievement for ImmunityBio, Inc. occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. On Mon
Intravesical gemcitabine/docetaxel as an alternative therapy for patients with non-muscle-invasive bladder cancer medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Treatment with the novel photodynamic therapy TLD-1433 activated by the laser TLC-3200 led to 6-, 12-, and 15-month complete response rates of 54%, 38%, and 37%, respectively, in patients with non–muscle invasive bladder cancer, meeting the primary and secondary end points of the phase 2 Study II trial.